NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

OGN

Organon & Co

May 01 • 04:00PM ET

9.45

Dollar change -3.48
Percentage change -26.91	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE MRK JNJ NVS ABBV LLY BMY GSK AZN BIIB

| Held by: IJR VTI VB VBR VXF IJS SPSM SLYV DES SCHA

Scroll to Statements

Index	-	P/E	2.83	EPS (ttm)	3.33	Insider Own	0.34%	Shs Outstand	259.96M	Perf Week	-22.03%
Market Cap	2.46B	Forward P/E	2.35	EPS next Y	4.02	Insider Trans	0.00%	Shs Float	259.08M	Perf Month	-33.12%
Income	864.00M	PEG	28.35	EPS next Q	0.90	Inst Own	81.33%	Short Float	6.73%	Perf Quarter	-40.83%
Sales	6.40B	P/S	0.38	EPS this Y	-5.92%	Inst Trans	2.13%	Short Ratio	4.40	Perf Half Y	-45.88%
Book/sh	1.83	P/B	5.16	EPS next Y	3.88%	ROA	6.87%	Short Interest	17.43M	Perf Year	-50.00%
Cash/sh	2.60	P/C	3.64	EPS next 5Y	0.10%	ROE	429.85%	52W Range	10.45 - 23.10	Perf YTD	-36.66%
Dividend Est.	1.19 (12.55%)	P/FCF	3.22	EPS past 5Y	-23.49%	ROI	9.15%	52W High	-59.09%	Beta	0.70
Dividend TTM	1.12 (11.85%)	Quick Ratio	1.11	Sales past 5Y	-6.67%	Gross Margin	58.02%	52W Low	-9.57%	ATR (14)	0.89
Dividend Ex-Date	Feb 24, 2025	Current Ratio	1.60	EPS Y/Y TTM	-16.11%	Oper. Margin	23.33%	RSI (14)	31.57	Volatility	6.91% 7.00%
Employees	10000	Debt/Eq	19.14	Sales Y/Y TTM	2.24%	Profit Margin	13.49%	Recom	2.75	Target Price	18.67
Option/Short	Yes / Yes	LT Debt/Eq	19.01	EPS Q/Q	-80.29%	Payout	33.59%	Rel Volume	7.82	Prev Close	12.93
Sales Surprise	0.32%	EPS Surprise	14.09%	Sales Q/Q	-0.38%	Earnings	May 01 BMO	Avg Volume	3.96M	Price	9.45
SMA20	-20.30%	SMA50	-31.58%	SMA200	-43.66%	Trades		Volume	30,980,440	Change	-26.91%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-06-24	Downgrade	JP Morgan	Neutral → Underweight	$18 → $20
Nov-03-23	Downgrade	Goldman	Buy → Neutral	$33 → $16
Sep-21-23	Initiated	Barclays	Overweight	$28
Mar-16-23	Initiated	Raymond James	Outperform	$33
Oct-14-22	Downgrade	BofA Securities	Neutral → Underperform	$27 → $25
Sep-06-22	Upgrade	Piper Sandler	Neutral → Overweight	$37 → $34
Aug-05-22	Downgrade	BofA Securities	Buy → Neutral	$40 → $37
Apr-27-22	Initiated	Goldman	Buy	$40
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$35
Oct-07-21	Initiated	Piper Sandler	Neutral	$35
Sep-01-21	Initiated	BofA Securities	Buy	$43
Jul-22-21	Initiated	Citigroup	Buy	$35
Jun-15-21	Initiated	JP Morgan	Neutral	$38
Jun-11-21	Initiated	Morgan Stanley	Equal-Weight	$33
Jun-10-21	Initiated	Evercore ISI	Outperform

Show Previous Ratings

May-01-25 11:31AM	Organon & Co. (OGN) Q1 2025 Earnings Call Transcript (Seeking Alpha) -26.91%
10:30AM	Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Organon (OGN) Q1 Earnings Surpass Estimates (Zacks)
07:00AM	Organon Reports Results for the First Quarter Ended March 31, 2025 (Business Wire)
Apr-28-25 09:15AM	Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
01:13PM	Loading…
Apr-27-25 01:13PM	3 Cash-Producing Stocks with Questionable Fundamentals (StockStory)
Apr-25-25 06:00PM	Organon (OGN) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
10:00AM	BrightSpring Health Services, Inc. (BTSG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:00AM	Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-24-25 10:01AM	Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for (Zacks) +5.48%
Apr-22-25 07:10AM	Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.74%
Apr-21-25 05:25PM	Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-15-25 05:00PM	Organon Appoints Ramona A. Sequeira to the Companys Board of Directors (Business Wire)
07:31AM	Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 (Business Wire)
06:00PM	Loading…
Apr-14-25 06:00PM	Organon (OGN) Laps the Stock Market: Here's Why (Zacks)
09:00AM	Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know (Zacks)
Apr-10-25 09:13AM	Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength? (Zacks) -9.57%
Apr-08-25 09:21PM	Lightning Round: ServiceNow is an expensive stock in a market that no longer loves expensive stocks (CNBC TV) -6.95% +8.50%
05:07AM	Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment (StockStory)
Apr-07-25 05:06AM	Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Apr-03-25 05:50PM	Organon (OGN) Stock Moves -1.83%: What You Should Know (Zacks) -9.69%
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-02-25 12:10PM	Why Organon (OGN) Could Beat Earnings Estimates Again (Zacks)
08:50AM	Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Apr-01-25 09:00AM	Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock (Zacks) -5.10%
07:30AM	Organon Acquires TOFIDENCE (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA (tocilizumab) Injection, for Intravenous Infusion in the U.S. (Business Wire)
Mar-28-25 05:50PM	Organon (OGN) Stock Moves -0.34%: What You Should Know (Zacks)
06:00AM	European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta (pertuzumab) Biosimilar Candidate HLX11 (Business Wire)
Mar-27-25 06:00PM	Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
05:50PM	Loading…
Mar-21-25 05:50PM	Organon (OGN) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Mar-19-25 09:00AM	Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-10-25 12:01AM	MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO (PR Newswire)
Mar-08-25 09:00AM	New Analysis of Organon's VTAMA (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older (Business Wire)
Feb-13-25 07:30AM	Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024 (Business Wire) +11.02%
Jan-23-25 07:30AM	Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025 (Business Wire)
Jan-12-25 09:27AM	Is Organon Co. (OGN) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Dec-19-24 07:30AM	Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-24 07:40AM	FDA approves Organons VTAMA cream, 1% for the treatment for AD (TipRanks)
Dec-16-24 07:30AM	FDA Approves VTAMA (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older (Business Wire)
Nov-05-24 07:29AM	Update on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older (Business Wire)
Oct-31-24 07:30AM	Organon Reports Results for the Third Quarter Ended September30, 2024 (Business Wire)
04:43AM	Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14 (Pharmaceutical Business Review)
Oct-30-24 06:00AM	US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) (Business Wire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Oct-09-24 09:35AM	Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:30AM	Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 (Business Wire)
Oct-08-24 08:01AM	Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands (PR Newswire)
Oct-02-24 02:05PM	Final Trades: Organon, Howmet and the PSQ (CNBC TV)
Sep-30-24 06:00AM	Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta (pertuzumab) Biosimilar Candidate HLX11 (Business Wire)
Sep-26-24 09:50AM	Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada (PR Newswire)
Sep-25-24 09:05AM	Are Options Traders Betting on a Big Move in Organon (OGN) Stock? (Zacks)
Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Aug-20-24 07:30AM	Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets (Business Wire)
Aug-06-24 07:30AM	Organon Reports Results for the Second Quarter Ended June 30, 2024 (Business Wire) -7.63%
Aug-02-24 08:48AM	Do Options Traders Know Something About Organon (OGN) Stock We Don't? (Zacks)
Jul-24-24 12:00PM	Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jul-09-24 06:00PM	Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
07:30AM	Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024 (Business Wire)
Jun-28-24 09:41AM	Do Options Traders Know Something About Organon (OGN) Stock We Don't? (Zacks)
Jun-26-24 06:00PM	Organon (OGN) Stock Sinks As Market Gains: Here's Why (Zacks)
01:35PM	Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now (InvestorPlace)
09:00AM	Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jun-20-24 06:00PM	Organon (OGN) Advances While Market Declines: Some Information for Investors (Zacks)
Jun-12-24 09:00AM	Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jun-03-24 09:35AM	Organon (OGN) Just Overtook the 20-Day Moving Average (Zacks)
May-30-24 09:00AM	Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know (Zacks)
May-24-24 06:00AM	European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia and Xgeva (denosumab) Biosimilar Candidate HLX14 (Business Wire)
May-14-24 12:20PM	Surging Earnings Estimates Signal Upside for Organon (OGN) Stock (Zacks)
May-07-24 08:20PM	Organon Announces Pricing of $1.0 Billion Senior Notes Offering (Business Wire)
12:45PM	20 States with the Highest Fertility Rates in the US (Insider Monkey)
07:58AM	Organon Announces Proposed $1.0 Billion Senior Notes Offering (Business Wire)
May-03-24 12:37PM	Organon & Co. (NYSE:OGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 12:00PM	What Makes Organon (OGN) a New Buy Stock (Zacks)
08:55AM	Organon (OGN) Tops Q1 Earnings and Revenue Estimates (Zacks)
07:30AM	Organon Reports Results for the First Quarter Ended March 31, 2024 (Business Wire)
May-01-24 01:26PM	7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024 (InvestorPlace)
11:03AM	Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store? (Zacks)
10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-29-24 10:26AM	12 Under-the-Radar Stocks With Massive Upside for 2024 (Insider Monkey)
09:16AM	Stay Ahead of the Game With Organon (OGN) Q1 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Apr-25-24 10:01AM	Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline (Zacks)
Apr-22-24 06:15PM	Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
09:35AM	15 Best Affordable Dividend Stocks To Invest In Right Now (Insider Monkey)
Apr-12-24 11:08AM	5 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)
Apr-08-24 06:15AM	Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024 (Business Wire)
06:00AM	Phase 3 Comparative Clinical Study of Prolia and Xgeva (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints (Business Wire)
Apr-01-24 04:05PM	Dar Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-08-24 09:01AM	On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health (PR Newswire)
Mar-05-24 02:56AM	13 Best Pharma Dividend Stocks To Buy in 2024 (Insider Monkey)
Feb-20-24 08:00AM	Organon Announces HADLIMA (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary (Business Wire)
07:45AM	Organon Launches U.S. Grant Programs and Listening Tour as Part of 'Her Plan Is Her Power,' Reaching High-Need Communities To Help Reduce Unplanned Pregnancies (ACCESSWIRE)
Feb-16-24 09:47AM	Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 11:00AM	Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +13.81%
07:30AM	Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023 (Business Wire)
Feb-14-24 08:05AM	Do You Believe That Organon & Co. (OGN) is a Compelling Prospect for Long-Term, Patient Investors? (Insider Monkey)
Feb-01-24 07:30AM	Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024 (Business Wire)
Jan-12-24 06:53AM	Organon & Co (OGN) Fell on Missed Consensus (Insider Monkey)
Jan-10-24 07:33AM	Organons XACIATO (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older (Business Wire) +6.17%

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Falcione Aaron	Chief Human Resources Officer	Mar 31 '25	Option Exercise	18,732	59,237	Apr 02 05:45 PM
Karp Daniel	Executive VP, Corp. Dev.	Mar 31 '25	Option Exercise	34,677	44,515	Apr 02 05:44 PM
Stahler Rachel A	Chief Information Officer	Mar 31 '25	Option Exercise	18,334	78,994	Apr 02 05:43 PM
WALSH MATTHEW M	Chief Financial Officer	Mar 31 '25	Option Exercise	34,870	136,903	Apr 02 05:41 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Mar 31 '25	Option Exercise	8,865	20,552	Apr 02 05:40 PM
Weaver Kirke	Gen. Counsel & Corp. Secy.	Mar 31 '25	Option Exercise	21,376	45,668	Apr 02 05:39 PM
DiMarco Kathryn	Corporate Controller	Mar 31 '25	Option Exercise	23,435	40,211	Apr 02 05:35 PM
Nisita Vittorio	Head of Global Business Svcs	Mar 31 '25	Option Exercise	13,231	44,803	Apr 02 05:34 PM
Morrissey Joseph T. Jr.	Head of Manufacturing	Mar 31 '25	Option Exercise	21,483	73,275	Apr 02 05:33 PM
Ali Kevin	Chief Executive Officer	Mar 31 '25	Option Exercise	109,204	260,687	Apr 02 05:32 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Nov 07 '24	Option Exercise	6,446	13,987	Nov 08 04:17 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Aug 11 '24	Option Exercise	11,519	11,532	Aug 12 05:18 PM
Morrissey Joseph T. Jr.	Head of Manufacturing	May 04 '24	Option Exercise	3,604	42,406	May 07 04:07 PM
Nisita Vittorio	Head of Global Business Svcs	May 04 '24	Option Exercise	2,078	23,097	May 07 04:07 PM
Fiedler Susanne	Chief Commercial Officer	May 04 '24	Option Exercise	4,989	52,253	May 07 04:06 PM
Ali Kevin	Chief Executive Officer	May 04 '24	Option Exercise	22,161	147,504	May 07 04:06 PM
Weaver Kirke	Gen. Counsel & Corp. Secy.	May 04 '24	Option Exercise	1,248	29,516	May 07 04:06 PM
Falcione Aaron	Chief Human Resources Officer	May 04 '24	Option Exercise	2,770	31,364	May 07 04:05 PM
DiMarco Kathryn	Corporate Controller	May 04 '24	Option Exercise	1,248	21,398	May 07 04:05 PM
WALSH MATTHEW M	Chief Financial Officer	May 04 '24	Option Exercise	8,310	92,419	May 07 04:05 PM
Stahler Rachel A	Chief Information Officer	May 04 '24	Option Exercise	3,049	49,282	May 07 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OGN

Organon & Co

Upgrade your FINVIZ experience